PeptiDREAM announces to form a joint venture to develop drugs for COVID-19
November 12, 2020, Kawasaki, Japan - Japan's drug design venture PeptiDream vice president Keiichi Masuya announces PeptiDream will form a joint venture PeptiAID with four companies to development of the new drug for the treatment of COVID-19 at the company's headquarters in Kawasaki, suburban Tokyo on Thursday, November 12, 2020. PeptiDream developed PDPS technology to find peptide candidates targeting spike protein of coronavirus to enter human cells. PeptiAID will obtain PeptiDream's COVID-19 candidate compounds to enter clinical testing. (Photo by Yoshio Tsunoda/AFLO)